Development of a novel drug delivery system consisting of an antitumor agent tocopheryl succinate

Area of Science:

• Nanotechnology
• Drug Delivery Systems
• Oncology

Background:

• α-tocopheryl succinate (TS) is a promising anticancer agent that induces apoptosis.
• TS naturally forms nanovesicles (TS-NVs) for drug delivery.
• TS-NVs exhibit limitations in drug encapsulation stability and tumor targeting.

Purpose of the Study:

• To develop a more stable nanovesicle drug delivery system (DDS) for enhanced antitumor efficacy.
• To improve the stability and therapeutic potential of TS-based nanovesicles.
• To evaluate the anticancer efficiency and delivery capabilities of the novel system.

Main Methods:

• Formulation of novel TS-EPC-NVs by combining TS with egg phosphatidylcholine.
• Assessment of vesicle stability compared to TS-NVs.
• Evaluation of in vivo antitumor activity and intratumoral distribution.
• In vitro assessment of anticancer efficiency and cellular uptake mechanisms.
• Testing of siRNA encapsulation and knockdown efficiency.

Main Results:

• TS-EPC-NVs demonstrated significantly higher stability than TS-NVs.
• In vivo antitumor activity of TS-EPC-NVs was markedly more potent.
• Enhanced intratumoral distribution contributed to improved therapeutic effects.
• In vitro anticancer efficiency increased seven-fold, attributed to improved cellular uptake and cytosolic delivery.
• TS-EPC-NVs effectively encapsulated siRNA, achieving significant gene knockdown.

Conclusions:

• TS-EPC-NVs represent a novel and effective nanovesicle drug delivery system.
• The enhanced stability and delivery of TS-EPC-NVs improve antitumor efficacy.
• This system holds potential for delivering both the carrier and encapsulated therapeutic agents.